Adderall-XR

Phase 2Small molecule

NNew River Pharmaceuticals

Adderall-XR is one of 191 small molecule programs targeting Cognitive impairment. It is currently in Phase 2.

Indications

Total Trials

Active Trials

190

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive ImpairmentActive, not recruiting

Attention Deficit Hyperactivity DisorderActive, not recruiting

Cocaine DependenceActive, not recruiting

MemoryActive, not recruiting

Major Depressive DisorderActive, not recruiting

Cognitive ImpairmentPhase 2/Phase 3

Active, not recruiting

Attention Deficit Hyperactivity DisorderPhase 2/Phase 3

Active, not recruiting

Cocaine DependencePhase 2

Active, not recruiting

MemoryPhase 2

Active, not recruiting

Major Depressive DisorderPhase 1

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Major Depressive Disorder

#DrugCompanyPhaseTrials

Fetzima

AbbVie

Phase 3

9 2

ALKS 37

AAlkermes, Inc.

Phase 3

6 3

Desvenlafaxine SR

Pfizer

Phase 3

13 4

Brenipatide

Eli Lilly

Phase 3

—5

Esketamine Hydrochloride

TThe Second Hospital of Anhui Medical University

Phase 3

2 6

Seltorexant

Johnson & Johnson

Phase 3

5 7

Seroquel IR

Otsuka

Phase 3

1 8

CYB003

CCybin IRL Limited

Phase 3

3 9

NBI-1065845

Neurocrine Biosciences

Phase 3

6 10

Minocyclin

UUniversity of Southern California

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Attention Deficit Hyperactivity Disorder2 trials

Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence

Completed·NNew York State Psychiatric Institute·Phase 2/3·NCT00553319·139 enrolled

Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder

Completed·NNew York State Psychiatric Institute·Phase 2/3·NCT02803229·33 enrolled

Cocaine Dependence1 trial

A Placebo-Controlled Study of Mixed Amphetamine Salts and Topiramate for the Treatment of Cocaine Dependence

Completed·NNew York State Psychiatric Institute·Phase 2·NCT00421603·81 enrolled

MPA1 trial

A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall

Completed·NNYU Langone Health·Phase 4·NCT00468143·62 enrolled

Major Depressive Disorder1 trial

Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder

Enrolling by invitation·UUniversity of California, Los Angeles·Phase 1·NCT04509102·30 enrolled

Children1 trial

NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD

Completed·NNew River Pharmaceuticals·Phase 2·NCT00557011·52 enrolled

3 more indications

Memory1 trial

Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression

Terminated·UUniversity of South Florida·Phase 2·NCT00069927·12 enrolled

Biomarkers1 trial

Biomarkers of ADHD Treatment Response

Completed·—·Phase 1·NCT05650775·16 enrolled

Cognitive impairment1 trial

Adderall XR and Cognitive Impairment in MS

Active, not recruiting·SSarah Morrow·Phase 2/3·NCT02676739·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Adderall-XR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Adderall-XR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Adderall-XR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — New River Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNew River Pharmaceuticals

Adderall-XR

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Attention Deficit Hyperactivity Disorder2 trials

Cocaine Dependence1 trial

MPA1 trial

Major Depressive Disorder1 trial

Children1 trial

Memory1 trial

Biomarkers1 trial

Cognitive impairment1 trial

References

Drug Info

Quick Facts

Related News